Tenax Therapeutics, Inc., a specialty pharmaceutical company, focused on the identification, development, and commercialization of a portfolio of products for the critical care market in the United States and Canada. It focuses on the development and commercialization of pharmaceutical products containing levosimendan, 2.5 mg/ml concentrate for solution for infusion/5ml vial for use in the reduction of morbidity and mortality in cardiac surgery patients at risk for developing Low Cardiac Output Syndrome. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is headquartered in Morrisville, North Carolina.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Commercial physical research
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:TENX
CUSIPN/A
Phone919-855-2100
Debt
Debt-to-Equity RatioN/A
Current Ratio22.55
Quick Ratio22.55
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual Sales$40,000.00
Price / Sales195.39
Cash FlowN/A
Price / CashN/A
Book Value$6.29 per share
Price / Book0.86
Profitability
EPS (Most Recent Fiscal Year)N/A
Net Income$-8,830,000.00
Net MarginsN/A
Return on Equity-70.29%
Return on Assets-63.13%
Miscellaneous
Employees8
Outstanding Shares1,450,000
Market Cap$8.79 million
Tenax Therapeutics (NASDAQ:TENX) Frequently Asked Questions
What is Tenax Therapeutics' stock symbol?
Tenax Therapeutics trades on the NASDAQ under the ticker symbol "TENX."
When did Tenax Therapeutics' stock split? How did Tenax Therapeutics' stock split work?
Shares of Tenax Therapeutics reverse split on the morning of Monday, February 26th 2018. The 1-20 reverse split was announced on Friday, February 23rd 2018. The number of shares owned by shareholders was adjusted after the market closes on Friday, February 23rd 2018. An investor that had 100 shares of Tenax Therapeutics stock prior to the reverse split would have 5 shares after the split.
How were Tenax Therapeutics' earnings last quarter?
Tenax Therapeutics Inc (NASDAQ:TENX) announced its earnings results on Tuesday, August, 14th. The specialty pharmaceutical company reported ($1.29) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($1.00) by $0.29. View Tenax Therapeutics' Earnings History.
Who are some of Tenax Therapeutics' key competitors?
Who are Tenax Therapeutics' key executives?
Tenax Therapeutics' management team includes the folowing people:
- Mr. Anthony A. DiTonno, Chief Exec. Officer (Age 70)
- Mr. Michael B. Jebsen, Pres & CFO (Age 47)
- Mr. John P. Kelley, Consultant (Age 64)
- Ms. Nancy J. M. Hecox, Exec. VP of Legal Affairs, Gen. Counsel & Corp. Sec.
- Maria Isabel Tomargo, Assistant VP of Marketing & Sales
Has Tenax Therapeutics been receiving favorable news coverage?
Media stories about TENX stock have been trending positive on Saturday, according to Accern. The research group scores the sentiment of press coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Tenax Therapeutics earned a media and rumor sentiment score of 0.28 on Accern's scale. They also assigned news articles about the specialty pharmaceutical company an impact score of 48.98 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company's share price in the near term. View Recent Headlines for Tenax Therapeutics.
Who are Tenax Therapeutics' major shareholders?
Tenax Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional investors include Renaissance Technologies LLC (5.75%). Company insiders that own Tenax Therapeutics stock include Gerald T Proehl and Ronald R Blanck. View Institutional Ownership Trends for Tenax Therapeutics.
Which institutional investors are buying Tenax Therapeutics stock?
TENX stock was bought by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC. Company insiders that have bought Tenax Therapeutics stock in the last two years include Gerald T Proehl and Ronald R Blanck. View Insider Buying and Selling for Tenax Therapeutics.
How do I buy shares of Tenax Therapeutics?
Shares of TENX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Tenax Therapeutics' stock price today?
One share of TENX stock can currently be purchased for approximately $5.39.
How big of a company is Tenax Therapeutics?
Tenax Therapeutics has a market capitalization of $8.79 million and generates $40,000.00 in revenue each year. Tenax Therapeutics employs 8 workers across the globe.
How can I contact Tenax Therapeutics?
Tenax Therapeutics' mailing address is ONE COPLEY PARKWAY SUITE 490, MORRISVILLE NC, 27560. The specialty pharmaceutical company can be reached via phone at 919-855-2100 or via email at [email protected]
MarketBeat Community Rating for Tenax Therapeutics (NASDAQ TENX)
MarketBeat's community ratings are surveys of what our community members think about Tenax Therapeutics and other stocks. Vote "Outperform" if you believe TENX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TENX will underperform the S&P 500 over the long term. You may vote once every thirty days.
